Evaluating The ADHD Medication VYVANSE CII Demonstrated No Change In Pharmacokinetic Profile Of VYVANSE When Coadministered With Prilosec OTC 40 Mg
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced results of a study showing that coadministration of the ADHD medication VYVANSE® (lisdexamfetamine dimesylate) CII with the proton pump inhibitor (PPI) Prilosec OTC® 40 mg (20 mg X 2), did not alter the median time it took for maximum plasma concentration of d-amphetamine to be reached in the subjects evaluated.
More: continued here
Filed under: ADHD on June 1st, 2009
You must be logged in to post a comment.